Employers Argue For Expansion Of Biosimilars To Help Lower Costs

By Ariel Cohen / April 1, 2020 at 12:40 PM
The ERISA Industry Committee released Tuesday (March 31) research findings of the potential savings to employers and employees from using more biosimilars. The study, which coincides with the 10th anniversary of the law that created biosimilars, found that although biologics make up less than 1% of prescriptions, they account for 40% of employer’s total drug spending. Also, biologics spending accounted for 93% of growth in drug spending from 2014-2017, yet only two biologics today face “meaningful” biosimilar competition. “The hope...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.